![](https://ml.globenewswire.com/media/97e9dd42-3978-4192-b1aa-dd84c7948079/medium/spring-trial-liver-stiffness-measurements-improved-in-cm-101.png)
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints ...
First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing …